enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Mounjaro vs. Ozempic: Which One Is Best for Me to Try for ...

   www.aol.com/mounjaro-vs-ozempic-one-best...

   A 2023 systematic review and meta-analysis looked into 14 trials of tirzepatide on more than 11,000 people with type 2 diabetes. It found that doses of 5 milligrams (mg), 10 milligrams and 15 ...

3. Is oral semaglutide a promising alternative in treating ... - AOL

   www.aol.com/oral-semaglutide-promising...

   Semaglutide, the active ingredient in diabetes drugs that have also become popular as a weight-loss aid, is primarily available in injectable form. This includes the two most widely used drugs ...

4. Semaglutide - Wikipedia

   en.wikipedia.org/wiki/Semaglutide

   The study focused on metformin and GLP-1 drugs, including semaglutide, tirzepatide and liraglutide. Among nearly 13,000 individuals with both diabetes and asthma, metformin lowered the risk of asthma attacks by 30%, and adding a GLP-1 drug further reduced it by 40%. [121]

5. Octreotide - Wikipedia

   en.wikipedia.org/wiki/Octreotide

   Octreotide can reduce the intestinal reabsorption of ciclosporin, possibly making it necessary to increase the dose. [20] People with diabetes mellitus might need less insulin or oral antidiabetics when treated with octreotide, as it inhibits glucagon secretion more strongly and for a longer time span than insulin secretion. [15]

6. GLP-1 drugs like Ozempic may protect brain health, several ...

   www.aol.com/glp-1-drugs-ozempic-may-170000610.html

   GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding in weight loss in people who have type 2 diabetes or obesity. A new ...

7. Meglitinide - Wikipedia

   en.wikipedia.org/wiki/Meglitinide

   A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.